Abstract: The invention concerns an implant that comprises an anterior part and a posterior part extending along a longitudinal axis and having respectively an anterior (A) and a posterior pole (E) both located on axis. The anterior and posterior parts extend each radially relative to axis, on either side thereof, the anterior and posterior parts having each two portions located on both sides of axis respectively when viewed in a sagittal plane. Each portion of the anterior part has a radial extension that increases from anterior pole (A) to a point (B, B?) where the anterior part ends and the posterior part begins, each portion of the posterior part having a radial extension decreasing from point (B, B?) to the posterior pole (E). The outer outline of each portion of the anterior part forms a curve having a radius of curvature that is greater at anterior pole (A) than at point (B, B?).

Abstract: The invention concerns an implant that comprises an anterior part and a posterior part extending along a longitudinal axis and having respectively an anterior (A) and a posterior pole (E) both located on axis. The anterior and posterior parts extend each radially relative to axis, on either side thereof, the anterior and posterior parts having each two portions located on both sides of axis respectively when viewed in a sagittal plane. Each portion of the anterior part has a radial extension that increases from anterior pole (A) to a point (B, B?) where the anterior part ends and the posterior part begins, each portion of the posterior part having a radial extension decreasing from point (B, B?) to the posterior pole (E). The outer outline of each portion of the anterior part forms a curve having a radius of curvature that is greater at anterior pole (A) than at point (B, B?).

Abstract: The invention concerns an iris cover implant intended to cover at least partially the iris of an eye, the cover implant comprising a body having a first face that is an opaque face and, on an opposite second face, at least one attachment member that extends outwardly from the body and is fixed thereto, the at least one attachment member comprising at least two clamping portions that are able to attach the body to an iris of an eye by clamping.

Abstract: A commercial site generates at least one identification badge in which a customer identifier and, if necessary, a customer password are stored. The commercial site assigns an account to the Identification badge. A diagnosis and advice site receives, from the commercial site, a supply of Identification badges and assigns one of the Identification badges to a customer. The diagnosis and advice site creates, in the commercial site, a shopping cart in the account assigned to the Identification badge entrusted to the customer. The customer is connected to the commercial site via a customer terminal by presenting the customer identifier and customer password borne by the identification badge, and the customer completes his or her account with his or her personal information. The commercial site allows only products listed in the shopping cart created by the diagnosis and advice site to be delivered to the customer.

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: A method of treating glaucoma or other eye disease in a patient is provided. The method includes injecting an eye of the patient with a cohesive monophasic gel containing cross-linked hyaluronic acid or its salt. The injection can be under the scleral flap and/or conjunctiva of the eye, thereby creating and maintaining a conjunctival bleb, and/or the injection can be in the supra-scleral and/or supra-choroidal (sub-scleral) space of the eye thereby reducing the intraocular pressure.

Abstract: An intraocular implant (1) including an optical portion (2) and a haptic portion (3), the haptic portion including two diametrically opposite haptic systems (3a, 3b), characterized in that each of the haptic systems (3a, 3b) includes two substantially identical haptics (4, 5) interconnected by their respective distal ends (4a, 5a), the respective proximal ends (4b, 5b) of the two haptics (4, 5) being connected to the optical portion (2) via a stalk (6), the width of each of the haptics (4, 5) decreasing continuously all along the haptic toward the distal end (4a, 5a).

Abstract: A method of treating glaucoma or other eye disease in a patient is provided. The method includes injecting an eye of the patient with a cohesive monophasic gel containing cross-linked hyaluronic acid or its salt. The injection can be under the scleral flap and/or conjunctiva of the eye, thereby creating and maintaining a conjunctival bleb, and/or the injection can be in the supra-scleral and/or supra-choroidal (sub-scleral) space of the eye thereby reducing the intraocular pressure.

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: Eye diseases such as glaucoma can be treated using a composition containing cross-linked hyaluronic acid or a cross-linked salt of hyaluronic acid such as sodium hyalurate. The composition can be a monophasic gel. The composition can include a cross-linking agent such as 1,4-butanediol diglycidylether. The composition can contains about 2.25% (w/w) of the salt of hyaluronic acid. The composition can have a cross-linking rate of about 0.5 to 50%.

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: An intraocular implant (1) including an optical portion (2) and a haptic portion (3), the haptic portion including two diametrically opposite haptic systems (3a, 3b), characterized in that each of the haptic systems (3a, 3b) includes two substantially identical haptics (4, 5) interconnected by their respective distal ends (4a, 5a), the respective proximal ends (4b, 5b) of the two haptics (4, 5) being connected to the optical portion (2) via a stalk (6), the width of each of the haptics (4, 5) decreasing continuously all along the haptic toward the distal end (4a, 5a).

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: A cartridge for an intraocular implant includes a loading chamber and an injection chamber communicating in a proximal portion of the cartridge. The cartridge further includes a piston chamber including a zone for communication with the loading chamber in a distal portion of the cartridge. The piston chamber includes a piston with an actuation end arranged to penetrate the loading chamber and to urge an intraocular implant located in the loading chamber through the injection chamber. An intraocular implant injector can include such a cartridge.

Abstract: Eye diseases such as glaucoma can be treated using a composition containing cross-linked hyaluronic acid or a cross-linked salt of hyaluronic acid such as sodium hyalurate. The composition can be a monophasic gel. The composition can include a cross-linking agent such as 1,4-butanediol diglycidylether. The composition can contains about 2.25% (w/w) of the salt of hyaluronic acid. The composition can have a cross-linking rate of about 0.5 to 50%.

Abstract: The invention relates to an improved intraocular lens. According to the invention, the haptic (3) support part (4), elevation view, takes the form of a flat, closed, semi-circular loop having a constant thickness at rest. The proximal end of the loop extends from the distal part of a connecting stalk (5) which extends essentially tangential to the periphery of the optical part (2) and in parallel with the vertical diameter (d1) of the optical part. The haptic (3) support part (4) forms an angle of approximately 30° with the horizontal diameter (d2) of the optical part (2).

Abstract: The invention relates to an ocular device which permits the avoidance of the phenomenon of photophobia and the method for production thereof. The device comprises one or more chromophores which absorb light in the wavelengths between 400 and 575 nm (blue-green light) and which are dispersed, after the placement in or on the eye, in the surrounding body fluids in several weeks to several months depending on the concentration of the chromophores. The device is produced by conditioning of the non-colored ocular device in an aqueous solution of the chromophore(s) in the shade.

Abstract: The invention relates to a folder module for folding a flexible intraocular implant for injection into the eye of a patient. The module comprises two jaws that are movable relative to each other, each jaw having a folder wall constituted by a portion of a cylindrical surface, and a plane wall secured to the folder wall, the two plane walls lying in parallel planes; a pivot axis orthogonal to the plane walls to control relative pivoting movement of one jaw relative to the other; one of the jaws being capable of occupying relative to the other a first position in which said plane walls are offset relative to each other; a second position in which the plane walls face each other so as to define an implant confinement volume; and a third position in which the folder walls meet each other to define a folder chamber enabling the implant to be finally folded.

Abstract: The invention relates to a folder module for folding a flexible intraocular implant for injection into the eye of a patient. The module comprises two jaws that are movable relative to each other, each jaw having a folder wall constituted by a portion of a cylindrical surface, and a plane wall secured to the folder wall, the two plane walls lying in parallel planes; a pivot axis orthogonal to the plane walls to control relative pivoting movement of one jaw relative to the other; one of the jaws being capable of occupying relative to the other a first position in which said plane walls are offset relative to each other; a second position in which the plane walls face each other so as to define an implant confinement volume; and a third position in which the folder walls meet each other to define a folder chamber enabling the implant to be finally folded.

Abstract: The invention relates to an intraocular implant comprising an optical portion presenting an anterior optical surface (24) and a posterior optical surface (26), and at least one haptic element (12, 14), each haptic element presenting a connection zone at the periphery of the optical portion. Outside the connection zones, the optical portion further comprises a cylindrical side face of diameter D1 connected to the posterior optical surface of the optical portion. The posterior optical surface (26) is bounded by a circle of diameter D1. In each connection zone, the implant comprises a radial extension (30) presenting an anterior face (30a), a posterior face (30b), and a side face (30c) substantially disposed on a ruled surface of diameter D2 where D2>D1, and presenting a length h? in the direction of the axis, said length h? being substantially equal to h. The posterior face (30b) of each extension is disposed on the spherical cap containing the posterior optical surface.